P&G Pharma Keeps Low Profile In Reorganization; Squeezes In With Charmin
Executive Summary
Procter & Gamble has ambitious plans for growing its health care business - but the role for its prescription drugs business is likely to remain decidedly low-key
You may also be interested in...
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
P&G Taps Lafley To Turn "Tide" In Earnings: Pepper Returns As Chairman
Procter & Gamble CEO-elect A.G. Lafley will inherit the task of settling the appropriate size for P&G's investment in the pharmaceutical business.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011